Eisai Co Ltd Spons A (ESALY) 52.1500 $ESALY
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
FDA clears Eisai drug for thyroid cancer
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 10:02AM CST
Anticancer Agent Lenvatinib Phase III Trial Results Published In New England Journal of Medicine
JCN Newswire - Thu Feb 12, 2:01AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that the results from the Phase III SELECT trial of lenvatinib mesylate (lenvatinib), a novel investigative anticancer agent for patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC), were published in the New England Journal of Medicine (NEJM) on February 12, 2015. This marks the first time that a journal article on a Phase III trial of a systemic therapy in thyroid cancer has been published in the NEJM.
Notice Regarding Eisai's Options Relating To Biogen Idec's Investigational Anti-Alzheimer's Disease Treatments
JCN Newswire - Wed Feb 04, 10:21PM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today further details of the options that it has as part of the agreement to jointly develop and commercialize its investigational next generation Alzheimer's disease (AD) treatment candidates E2609, a BACE inhibitor, and BAN2401, an anti-amyloid beta (A Beta) protofibril antibody, with Biogen Idec (Headquarters: Massachusetts, the United States, CEO: George A. Scangos), which was initially announced on March 5, 2014 ("Collaboration Agreement" . This notice is made to coincide with the annual report (10-K) publicly disclosed by Biogen Idec on February 4 (EST).
BIIB: 391.66 (-0.45)
Eisai's Phase II Trial of Anticancer Agent Lenvatinib in Renal Cell Carcinoma Meets Primary Endpoint
JCN Newswire - Sun Feb 01, 6:37PM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that the Phase II part of a Phase I/II clinical trial (Study 205) of its in-house developed anticancer agent lenvatinib mesylate (lenvatinib) in unresectable advanced or metastatic renal cell carcinoma has met its primary endpoint.
What Investors Should Do About Imminent Obesity Drug Approvals In Europe
Rx Stocks - at Seeking Alpha - Tue Jan 27, 7:38AM CST
ZFGN: 39.06 (+0.92), OREX: 5.55 (+0.10), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), TEVA: 56.77 (-0.58), GSK: 47.94 (+1.99), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Eisai and Ajinomoto Pharmaceuticals Launch Branched-Chain Amino Acid Formula Livamin Oral Granules in The Philippines
JCN Newswire - Mon Jan 26, 1:55AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" and Ajinomoto Pharmaceuticals Co., Ltd. (Headquarters: Tokyo, President: Takashi Nagamachi, "Ajinomoto Pharmaceuticals" announced today that LIVAMIN Oral Granules (granules of isoleucine, leucine and valine, brand name in Japan: LIVACT Granules), a branched-chain amino acid formula, was launched in the Philippines.
Eisai Listed In Global 100 Sustainability Index for Third Consecutive Year
JCN Newswire - Fri Jan 23, 3:53AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that it has been listed in the 2015 Global 100 Most Sustainable Corporations in the World (Global 100) Index, a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai's third inclusion on the list in as many years, and Eisai is the only company from Japan to be included in 2015.
Forget Pills! Could This Device Put an End to Obesity in America?
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 17, 6:21AM CST
Source: Behavorial Risk Factor Surveillance Systems, Centers for Disease Control and Prevention. Obesity might be sometimes overlooked as a disease that needs immediate attention, but the reality is it's a serious condition that can lead to a...
OREX: 5.55 (+0.10), ZFGN: 39.06 (+0.92), ETRM: 1.21 (+0.06), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Why VIVUS, Inc. Stock Descended 14% in December
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 09, 8:03AM CST
What: Shares of VIVUS , a biopharmaceutical company focused on developing therapies to treat obesity and erectile dysfunction, tumbled 14% in December, based on data from S&P Capital IQ , after rival Orexigen Therapeutics received a...
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Eisai Listed for 13th Consecutive Year in FTSE4GOOD Index Series, an Index for Socially Responsible Investment
JCN Newswire - Wed Dec 17, 3:25AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that it has been listed for the 13th consecutive year since 2002 in the FTSE4Good Index Series, a global index for socially responsible investment.
Eisai Demonstrates Efficacy of Investigational Dual Orexin Receptor Antagonist E2006 in Sleep Initiation and Maintenance Data from Phase II Clinical Trial for Insomnia
JCN Newswire - Wed Dec 10, 2:47AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that it has presented data from a Phase II clinical study (Study 201) on its in-house-developed investigational dual orexin receptor antagonist (DORA) E2006 in patients with insomnia disorder at the 53rd American College of Neuropsychopharmacology (ACNP) Annual Meeting held from December 7 through 11, 2014, in Phoenix, Arizona in the United States. In the study, E2006 demonstrated a statistically significant improvement in sleep initiation and sleep maintenance without increasing next-day residual sleepiness when compared with placebo.
RedHill submits MAA for ondansetron
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:38AM CST
INSY: 51.50 (-0.66), TSRO: 38.49 (-0.83), HRTX: 10.29 (+0.39), RDHL: 12.69 (+0.04), GWPH: 78.09 (+1.70), OPK: 13.80 (-0.28), GALE: 1.68 (+0.06)
Eisai Presents Results from Phase III Trial of Antiepileptic Drug Fycompa as Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures
JCN Newswire - Tue Dec 09, 2:36AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that it has presented the results from a Phase III clinical study (Study 332) of its in-house developed antiepileptic drug (AED) Fycompa (perampanel) in patients with primary generalized tonic-clonic (PGTC) seizures, one of the most severe forms of generalized seizures. The data was presented at the 68th American Epilepsy Society (AES) Annual Meeting held from December 5 to 9 in Seattle, Washington in the United States (Abstract No.: 2389). Furthermore, this presentation was selected by the AES for its official program, and was highlighted at a press conference on Sunday, December 7.
Could This Company Follow in Dendreon's Footsteps?
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 03, 10:11AM CST
When it comes to the investing world, the ultimate compliment you or your company can get is being compared to the likes of visionaries like Warren Buffett or iconic companies likes Apple or Coca-Cola . If there's an antithesis to the iconic...
KO: 41.99 (-0.18), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02), AAPL: 127.08 (+0.62)
AstraZeneca/Eli Lilly Start Mid-Stage Alzheimer's Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 2:30PM CST
AstraZeneca (AZN) and Eli Lilly (LLY) announced the initiation of the phase II/III AMARANTH study on AZD3293.
BIIB: 391.66 (-0.45), AZN: 69.96 (+0.20), LLY: 70.56 (+0.03)
Eisai to Present New Research on Halaven (Eribulin) at 37th Annual San Antonio Breast Cancer Symposium
JCN Newswire - Tue Dec 02, 1:45AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that new clinical study results on the company's novel anticancer agent Halaven (eribulin mesylate) will be presented during the 37th San Antonio Breast Cancer Symposium (SABCS). The symposium will be held from December 9 through 13, 2014, in San Antonio, Texas in the United States.
Eisai Establishes Holding Company Eisai China Holdings Ltd. in China
JCN Newswire - Sun Nov 30, 10:45PM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that it has established a holding company Eisai China Holdings Ltd. in Suzhou, Jiangsu Province, China. Eisai China Holdings Ltd. is a subsidiary of Eisai Asia Regional Services Pte. Ltd. which is Eisai's representative subsidiary for Asia located in Singapore.
Eisai Launches Anticancer Agent Halaven as Company's First Product in Brazil
JCN Newswire - Tue Nov 25, 9:25PM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that its Brazil subsidiary Eisai Laboratorios Ltda. (Location: San Paulo, "Eisai Brazil" has launched the anticancer agent Halaven (eribulin mesylate) in the country. This marks the Eisai Group's first product to be marketed by Eisai in Latin America.
Epizyme Gains on Positive Phase I Data on EPZ-6438 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 5:15PM CST
Epizyme, Inc. (EPZM) announced positive phase I study data on its oncology candidate, EPZ-6438 for advanced solid tumors and B-cell non-Hodgkin lymphomas.
CYTK: 7.78 (+1.29), BIIB: 391.66 (-0.45), EPZM: 21.58 (+0.08)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
FDA clears Eisai drug for thyroid cancer
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 10:02AM CST
Anticancer Agent Lenvatinib Phase III Trial Results Published In New England Journal of Medicine
JCN Newswire - Thu Feb 12, 2:01AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that the results from the Phase III SELECT trial of lenvatinib mesylate (lenvatinib), a novel investigative anticancer agent for patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC), were published in the New England Journal of Medicine (NEJM) on February 12, 2015. This marks the first time that a journal article on a Phase III trial of a systemic therapy in thyroid cancer has been published in the NEJM. Notice Regarding Eisai's Options Relating To Biogen Idec's Investigational Anti-Alzheimer's Disease Treatments
JCN Newswire - Wed Feb 04, 10:21PM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today further details of the options that it has as part of the agreement to jointly develop and commercialize its investigational next generation Alzheimer's disease (AD) treatment candidates E2609, a BACE inhibitor, and BAN2401, an anti-amyloid beta (A Beta) protofibril antibody, with Biogen Idec (Headquarters: Massachusetts, the United States, CEO: George A. Scangos), which was initially announced on March 5, 2014 ("Collaboration Agreement" . This notice is made to coincide with the annual report (10-K) publicly disclosed by Biogen Idec on February 4 (EST). BIIB: 391.66 (-0.45)
Eisai's Phase II Trial of Anticancer Agent Lenvatinib in Renal Cell Carcinoma Meets Primary Endpoint
JCN Newswire - Sun Feb 01, 6:37PM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that the Phase II part of a Phase I/II clinical trial (Study 205) of its in-house developed anticancer agent lenvatinib mesylate (lenvatinib) in unresectable advanced or metastatic renal cell carcinoma has met its primary endpoint. What Investors Should Do About Imminent Obesity Drug Approvals In Europe
Rx Stocks - at Seeking Alpha - Tue Jan 27, 7:38AM CST
ZFGN: 39.06 (+0.92), OREX: 5.55 (+0.10), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), TEVA: 56.77 (-0.58), GSK: 47.94 (+1.99), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Eisai and Ajinomoto Pharmaceuticals Launch Branched-Chain Amino Acid Formula Livamin Oral Granules in The Philippines
JCN Newswire - Mon Jan 26, 1:55AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
and Ajinomoto Pharmaceuticals Co., Ltd. (Headquarters: Tokyo, President: Takashi Nagamachi, "Ajinomoto Pharmaceuticals" announced today that LIVAMIN Oral Granules (granules of isoleucine, leucine and valine, brand name in Japan: LIVACT Granules), a branched-chain amino acid formula, was launched in the Philippines. Eisai Listed In Global 100 Sustainability Index for Third Consecutive Year
JCN Newswire - Fri Jan 23, 3:53AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that it has been listed in the 2015 Global 100 Most Sustainable Corporations in the World (Global 100) Index, a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai's third inclusion on the list in as many years, and Eisai is the only company from Japan to be included in 2015. Forget Pills! Could This Device Put an End to Obesity in America?
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 17, 6:21AM CST
Source: Behavorial Risk Factor Surveillance Systems, Centers for Disease Control and Prevention. Obesity might be sometimes overlooked as a disease that needs immediate attention, but the reality is it's a serious condition that can lead to a...
OREX: 5.55 (+0.10), ZFGN: 39.06 (+0.92), ETRM: 1.21 (+0.06), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Why VIVUS, Inc. Stock Descended 14% in December
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 09, 8:03AM CST
What: Shares of VIVUS , a biopharmaceutical company focused on developing therapies to treat obesity and erectile dysfunction, tumbled 14% in December, based on data from S&P Capital IQ , after rival Orexigen Therapeutics received a...
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Eisai Listed for 13th Consecutive Year in FTSE4GOOD Index Series, an Index for Socially Responsible Investment
JCN Newswire - Wed Dec 17, 3:25AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that it has been listed for the 13th consecutive year since 2002 in the FTSE4Good Index Series, a global index for socially responsible investment. Eisai Demonstrates Efficacy of Investigational Dual Orexin Receptor Antagonist E2006 in Sleep Initiation and Maintenance Data from Phase II Clinical Trial for Insomnia
JCN Newswire - Wed Dec 10, 2:47AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that it has presented data from a Phase II clinical study (Study 201) on its in-house-developed investigational dual orexin receptor antagonist (DORA) E2006 in patients with insomnia disorder at the 53rd American College of Neuropsychopharmacology (ACNP) Annual Meeting held from December 7 through 11, 2014, in Phoenix, Arizona in the United States. In the study, E2006 demonstrated a statistically significant improvement in sleep initiation and sleep maintenance without increasing next-day residual sleepiness when compared with placebo. RedHill submits MAA for ondansetron
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:38AM CST
INSY: 51.50 (-0.66), TSRO: 38.49 (-0.83), HRTX: 10.29 (+0.39), RDHL: 12.69 (+0.04), GWPH: 78.09 (+1.70), OPK: 13.80 (-0.28), GALE: 1.68 (+0.06)
Eisai Presents Results from Phase III Trial of Antiepileptic Drug Fycompa as Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures
JCN Newswire - Tue Dec 09, 2:36AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that it has presented the results from a Phase III clinical study (Study 332) of its in-house developed antiepileptic drug (AED) Fycompa (perampanel) in patients with primary generalized tonic-clonic (PGTC) seizures, one of the most severe forms of generalized seizures. The data was presented at the 68th American Epilepsy Society (AES) Annual Meeting held from December 5 to 9 in Seattle, Washington in the United States (Abstract No.: 2389). Furthermore, this presentation was selected by the AES for its official program, and was highlighted at a press conference on Sunday, December 7. Could This Company Follow in Dendreon's Footsteps?
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 03, 10:11AM CST
When it comes to the investing world, the ultimate compliment you or your company can get is being compared to the likes of visionaries like Warren Buffett or iconic companies likes Apple or Coca-Cola . If there's an antithesis to the iconic...
KO: 41.99 (-0.18), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02), AAPL: 127.08 (+0.62)
AstraZeneca/Eli Lilly Start Mid-Stage Alzheimer's Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 2:30PM CST
AstraZeneca (AZN) and Eli Lilly (LLY) announced the initiation of the phase II/III AMARANTH study on AZD3293.
BIIB: 391.66 (-0.45), AZN: 69.96 (+0.20), LLY: 70.56 (+0.03)
Eisai to Present New Research on Halaven (Eribulin) at 37th Annual San Antonio Breast Cancer Symposium
JCN Newswire - Tue Dec 02, 1:45AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that new clinical study results on the company's novel anticancer agent Halaven (eribulin mesylate) will be presented during the 37th San Antonio Breast Cancer Symposium (SABCS). The symposium will be held from December 9 through 13, 2014, in San Antonio, Texas in the United States. Eisai Establishes Holding Company Eisai China Holdings Ltd. in China
JCN Newswire - Sun Nov 30, 10:45PM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that it has established a holding company Eisai China Holdings Ltd. in Suzhou, Jiangsu Province, China. Eisai China Holdings Ltd. is a subsidiary of Eisai Asia Regional Services Pte. Ltd. which is Eisai's representative subsidiary for Asia located in Singapore. Eisai Launches Anticancer Agent Halaven as Company's First Product in Brazil
JCN Newswire - Tue Nov 25, 9:25PM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that its Brazil subsidiary Eisai Laboratorios Ltda. (Location: San Paulo, "Eisai Brazil" has launched the anticancer agent Halaven (eribulin mesylate) in the country. This marks the Eisai Group's first product to be marketed by Eisai in Latin America. Epizyme Gains on Positive Phase I Data on EPZ-6438 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 5:15PM CST
Epizyme, Inc. (EPZM) announced positive phase I study data on its oncology candidate, EPZ-6438 for advanced solid tumors and B-cell non-Hodgkin lymphomas.
CYTK: 7.78 (+1.29), BIIB: 391.66 (-0.45), EPZM: 21.58 (+0.08)
